Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data

References

• Napolitano M, Caso F, Scarpa R, et al. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893–1901.
   PubMed Web of Science ®Google Scholar
• Meier M, Sheth PB. Clinical spectrum and severity of psoriasis. Yawalkar N, editor. Management of psoriasis. Vol. 38, Curr Probl Dermatol. Basel, Karger; 2009. p. 1–20.
   Google Scholar
• Bagel J, Gold LS. Combining topical psoriasis treatment to enhance systemic and phototherapy: a review of the literature. J Drugs Dermatol. 2017 Dec 1;16(12):1209–1222.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF. Topical therapies for psoriasis: improving management strategies and patient adherence. Semin Cutan Med Surg. 2016;35(2 Suppl 2):S36–44.
   PubMedGoogle Scholar
• Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–374.
   PubMed Web of Science ®Google Scholar
• Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.
   PubMed Web of Science ®Google Scholar
• Patruno C, Ayala F, Megna M, et al. Patient-physician relationship in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2012;78(2):228.
   PubMed Web of Science ®Google Scholar
• Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168(5):954–967.
   PubMed Web of Science ®Google Scholar
• Mason AR, Mason JM, Cork MJ, et al. Topical treatments for chronic plaque psoriasis (Review). Cochrane Lib. 2013;2009(2):CD005028
   Google Scholar
• Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011 Jun;25(Suppl 4):3–8.
   PubMedGoogle Scholar
• Hendriks AG, Keijsers RR, de Jong EM, et al. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(8):931–951.
   PubMed Web of Science ®Google Scholar
• Albrecht L, Bourcier M, Ashkenas J, et al. Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. J Cutan Med Surg. 2011;15(6):309–321.
   PubMed Web of Science ®Google Scholar
• Bury Y, Ruf D, Hansen CM, et al. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. J Invest Dermatol. 2001;116(5):785–792.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol. 1995 May;132(5):675–682.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC. In vivo effects of vitamin D3 analogues. J Dermatol Treat. 1998;9(Suppl. 3):S25–9.
   Google Scholar
• Barna M, Bos JD, Kapsenberg ML, et al. Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br J Dermatol. 1997 Apr;136(4):536–541.
   PubMed Web of Science ®Google Scholar
• Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag. 2008 Feb;4(1):141–148.
   PubMedGoogle Scholar
• Simonsen L, Høy G, Didriksen E, et al. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm. 2004;30(10):1095–1102.
   PubMed Web of Science ®Google Scholar
• Hansen J Mixing the unmixable. Verbal communication at the Leo Satellite Symposium. 10th Congress of the European Academy of Dermatology and Venereology; Oct 10 –14; Munich, Germany. 2001.
   Google Scholar
• Guenther LC. Calcipotriol/betamethasone dipropionate: daivobet/dovobet. Therapy. 2005;2:343–348.
   Google Scholar
• Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol. 2004 Aug;43(8):611–617.
   PubMed Web of Science ®Google Scholar
• Rogalski C. Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability. Psoriasis (Auckl). 2015 Jun;8(5):97–107.
   Google Scholar
• Kuehl B, Shear NH. The evolution of topical formulations in psoriasis. Skin Therapy Lett. 2018 Jul;23(4):5–9.
   PubMedGoogle Scholar
• Patel NU, Felix K, Reimer D, et al. Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol. 2017;10:385–391.
   PubMed Web of Science ®Google Scholar
• Balak D, Carrascosa JM, Gregoriou S, et al. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus non-biologic systemic therapies for the treatment of plaque psoriasis in seven European countries. J Dermatolog Treat. 2020;1–24. doi:10.1080/09546634.2019.1707754.
   PubMed Web of Science ®Google Scholar
• Bewley AP, Shear NH, Calzavara-Pinton PG, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33(6):1107–1115.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Taclonex® ointment approval letter, Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021852TOC.cfm
   Google Scholar
• European Medicines Agency. Daivobet® review, Available from: https://www.ema.europa.eu/en/medicines/human/referrals/daivobet
   Google Scholar
• LEO Pharma Taclonex® ointment, prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021852s015lbl.pdf
   Google Scholar
• Abramovits W, Perlmutter A, Gupta AK. Taclonex (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment. Skinmed. 2006;5(3):136–138.
   PubMedGoogle Scholar
• Habjanič N, Koytchev R, Yankova R, et al. Therapeutic equivalence of two formulations of calcipotriol-betamethasone ointment: a multicentre, randomized, double-blind study in adult patients with chronic plaque psoriasis. Br J Dermatol. 2018;179(5):1189–1191.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Wasel N, Kragballe K, et al. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology. 2005;210:294–299.
   PubMed Web of Science ®Google Scholar
• van Geel MJ, Mul K, Oostveen AM, et al. Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171(2):363–369.
   PubMed Web of Science ®Google Scholar
• Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. European Journal of Dermatology : EJD. 2005 Jan-Feb;15(1):37–39.
   PubMed Web of Science ®Google Scholar
• Poulin Y. Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis. Skin Therapy Lett. 2002 Jun;7(6):1–3.
   PubMedGoogle Scholar
• Patel T, Bhutani T, Busse KL, et al. Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial. Cutis. 2011 Sep;88(3):149–154.
   PubMed Web of Science ®Google Scholar
• Downs AM. Dovobet ointment under occlusion overnight for troublesome scalp psoriasis. Acta Derm Venereol. 2006;86(1):57–58.
   PubMed Web of Science ®Google Scholar
• Habjanič N, Lužar-Stiffler V, Kerec-Kos M, et al. Efficacy of calcipotriol-betamethasone ointment in patients with mild to moderate plaque psoriasis: subgroup analyses. Dermatology. 2019;235(6):501–508.
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (DaivobetTM) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4): 389–393.
   PubMed Web of Science ®Google Scholar
• Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147(2):316–323.
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48–54.
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131–135.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H, et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150(6):1167–1173.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, et al. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209(4):308–313.
   PubMed Web of Science ®Google Scholar
• Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2006 Jan;20(1):39–44.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology. 2006;213(4): 319–326.
   PubMed Web of Science ®Google Scholar
• Duweb G, Alhaddar J, Elsherif B, et al. Calcipotriol-betamethasone ointment versus calcipotriol ointment in the treatment of psoriasis vulgaris. Drugs Exp Clin Res. 2005;31(5–6):175–179.
   PubMedGoogle Scholar
• Ortonne JP, Esposito M, Chimenti S, et al. Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial. J Eur Acad Dermatol Venereol. 2014;28(9):1226–1234.
   PubMed Web of Science ®Google Scholar
• Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol. 2008;88(3):279–280.
   PubMed Web of Science ®Google Scholar
• Cassano N, Vena GA. Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product. Acta Derm Venereol. 2007;87(1):85–86.
   PubMed Web of Science ®Google Scholar
• White S, Vender R, Thaçi D, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol. 2006;7(3):177–184.
   PubMed Web of Science ®Google Scholar
• Cassano N, Miracapillo A, Coviello C, et al. Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol. Clin Drug Investig. 2006;26(4):227–233.
   PubMed Web of Science ®Google Scholar
• Kircik LH. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. J Drugs Dermatol. 2011;10(8):878–882.
   PubMed Web of Science ®Google Scholar
• Vena GA, Galluccio A, Pezza M, et al. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study. J Dermatolog Treat. 2012 Aug;23(4):255–260.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163(2):402–411.
   PubMed Web of Science ®Google Scholar
• LEO Pharma Taclonex scalp® topical suspension, NDA Approval Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022185s000ltr.pdf
   Google Scholar
• European Medicines Agency. Daivobet® summary. [cited 2020 Mar 19]. Available from: https://www.ema.europa.eu/en/ema/index.jsp%3Fcurl%3Dpages/medicines/human/referrals/Daivobet/human_referral_000239.jsp%26mid%3DWC0b01ac0580024e9a
   Google Scholar
• LEO Pharma Taclonex® topical suspension, Prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022185s010lbl.pdf
   Google Scholar
• LEO Pharma Taclonex® topical suspension, Prescribing information Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022185s018lbl.pdf
   Google Scholar
• LEO Pharma Taclonex® topical suspension, Prescribing information. [cited 2020 Mar 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022185s027lbl.pdf
   Google Scholar
• Guenther LC. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol). Skin Therapy Lett. 2009 May;14(4):1–4.
   PubMedGoogle Scholar
• Saraceno R, Camplone G, D’Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat. 2014;25(1):30–33.
   PubMed Web of Science ®Google Scholar
• Buckley C, Hoffmann V, Jerry Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217(2):107–113.
   PubMed Web of Science ®Google Scholar
• Daudén E, Bewley A, Lambert J, et al. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 2):22–32.
   PubMedGoogle Scholar
• Queille-Roussel C, Clonier F, Olesen M. Alternative treatment with calcipotriol plus betamethasone dipropionate gel in psoriasis vulgaris using a short-contact approach. Br J Dermatol. 2014;171(6):1596–1598.
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, et al. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol. 2015;29(6):1156–1163.
   PubMed Web of Science ®Google Scholar
• Reich K, Zschocke I, Bachelez H, et al. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017;177(1):197–205.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Macheleidt O, Eicke C. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®-gel): results. J Dtsch Dermatol Ges. 2011 Oct;9(10):825–831.
   PubMed Web of Science ®Google Scholar
• Kontochristopoulos G, Kouris A, Chantzaras A, et al. Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris. An Bras Dermatol. 2016;91(2):160–166.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park CJ, Kim TY, et al. Optimal maintenance treatment with calcipotriol/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2017;31(3):483–489.
   PubMed Web of Science ®Google Scholar
• Bagel J, Levi E, Tyring S, et al. Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris. J Drugs Dermatol. 2014 Nov;13(11):1374–1379.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Debarre JM, Keddy-Grant J, et al. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age. Br J Dermatol. 2014;171(6):1470–1477.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Ganslandt C, Kurvits M, et al. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol. 2015;32(1):28–35.
   PubMed Web of Science ®Google Scholar
• Oostveen AM, de Jong EM, Donders AR, et al. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children’s quality of life in daily practice. J Eur Acad Dermatol Venereol. 2015;29(6):1193–1197.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Marcoux D, Kurvits M, et al. Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. J Eur Acad Dermatol Venereol. 2019. doi:10.1111/jdv.16077.
   Web of Science ®Google Scholar
• Ferris LK, Kupetsky E, Houston NA. A preliminary, open label, single-arm study of calcipotriene/betamethasone topical suspension as a supplement to non-biologic systemic therapy for psoriasis. J Clin Aesthet Dermatol. 2016 Apr;9(4):33–38.
   PubMedGoogle Scholar
• Tan ES, Oon HH. Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel. Indian J Dermatol Venereol Leprol. 2016 May-Jun;82(3):345–347.
   PubMed Web of Science ®Google Scholar
• Arango-Duque LC, Roncero-Riesco M, Usero Bárcena T, et al. Treatment of nail psoriasis with Pulse Dye Laser plus calcipotriol betametasona gel vs. Nd:YAGplus calcipotriol betamethasone gel: an intrapatient left-to-right controlled study. Actas Dermosifiliogr. 2017;108(2):140–144.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161(1):159–166.
   PubMed Web of Science ®Google Scholar
• Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010;49(11):1328–1333.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59(3):455–463.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170–176.
   PubMed Web of Science ®Google Scholar
• Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217(4): 321–328.
   PubMed Web of Science ®Google Scholar
• Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465–471.
   PubMed Web of Science ®Google Scholar
• Menter A, Gold LS, Bukhalo M, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol. 2013 Jan;12(1):92–98.
   PubMed Web of Science ®Google Scholar
• Ma L, Yang Q, Yang H, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Int J Dermatol. 2016;55(1):106–113.
   PubMed Web of Science ®Google Scholar
• Jemec GB, van de Kerkhof PC, Enevold A, et al. Significant one-week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. J Eur Acad Dermatol Venereol. 2011;25(1):27–32.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Enstilar®, Approval Letter. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207589Orig1s000Approv.pdf
   Google Scholar
• LEO Pharma communication of approval of Enstilar® in the EU Available from: https://www.leo-pharma.ca/Media-Centre/News/News-2016/LEO-Pharma-Receives-ScientificApproval-of-Enstilar%C2%AE-for-the-Treatment-of-Psoriasis-in-EU.aspx
   Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413–425.
   PubMed Web of Science ®Google Scholar
• Dattola A, Silvestri M, Bennardo L, et al. A novel vehicle for the treatment of psoriasis. Dermatol Ther. 2020;33(1):e13185.
   PubMed Web of Science ®Google Scholar
• Bagel J, Zapata J, Nelson E. A prospective, open-label study evaluating adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam in psoriasis patients with inadequate response to biologic therapy. J Drugs Dermatol. 2018 Aug 1;17(8):845–850.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Krakor M, Anger T, et al. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2017;233(6):425–434.
   PubMed Web of Science ®Google Scholar
• Pinter A, Thormann H, Angeletti F, et al. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clin Cosmet Investig Dermatol. 2018;9(11):451–459.
   Google Scholar
• Wu JJ, Veverka KA, Lu M, et al. Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States. J Dermatolog Treat. 2019;30(5):454–460.
   PubMed Web of Science ®Google Scholar
• Gallo L, Megna M, Cirillo T, et al. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. J Eur Acad Dermatol Venereol. 2019;33(7):1312–1315.
   PubMed Web of Science ®Google Scholar
• Anderko M, Navarro Triviño FJ, Sharples CL. Calcipotriol plus betamethasone dipropionate aerosol foam for scalp psoriasis. Clin Cosmet Investig Dermatol. 2019 Sep;17(12):699–705.
   Google Scholar
• Queille-Roussel C, Olesen M, Villumsen J, et al. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin Drug Investig. 2015;35(4):239–245.
   PubMed Web of Science ®Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris-A randomized phase II study. J Dermatolog Treat. 2016;27(2):120–127.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016 Feb;9(2):34–41.
   PubMedGoogle Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients with Psoriasis Vulgaris–a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468–1477.
   PubMed Web of Science ®Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119–126.
   PubMed Web of Science ®Google Scholar
• Paul C, Leonardi C, Menter A, et al. Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am J Clin Dermatol. 2017;18(3):405–411.
   PubMed Web of Science ®Google Scholar
• Stein Gold L, Lebwohl M, Menter A, et al. Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J Drugs Dermatol. 2016;1;15(8):951–957.
   PubMed Web of Science ®Google Scholar
• Pink AE, Jalili A, Berg P, et al. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol. 2019;33(6):1116–1123.
   PubMed Web of Science ®Google Scholar
• Jalili A, Lebwohl M, Stein Gold L, et al. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. J Eur Acad Dermatol Venereol. 2019;33(4):709–717.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ, Kircik LH. The effect of calcipotriene-betamethasone dipropionate aerosol foam versus vehicle on target lesions in moderate severity plaque psoriasis: focus on elbows and knees. J Drugs Dermatol. 2019 Apr 1;18(4):358–361.
   PubMed Web of Science ®Google Scholar
• Iversen L, Kurvits M, Marieke Snel-Prentø A, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate cutaneous aerosol foam treatment for psoriasis in patients with body surface area 5–15% and Physician’s global assessment >/=3. e-poster, 28th EADV Congress, 2019 Oct 9-13. Madrid, Spain.
   Google Scholar
• Stein Gold L, Villumsen J, Rosen M. Calcipotriol plus betamethasone dipropionate aerosol foam is effective, independent of body mass index and the extent and severity of psoriasis. Dermatol Ther (Heidelb). 2016 Dec;6(4):667–673.
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C, Rosen M, Clonier F, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate aerosol foam compared with betamethasone 17-valerate-medicated plaster for the treatment of psoriasis. Clin Drug Investig. 2017;37(4):355–361.
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol. 2015;29(12):2349–2355.
   PubMed Web of Science ®Google Scholar
• Gual A, Pau-Charles I, Molin S. Topical treatment for scalp psoriasis: comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice. J Dermatolog Treat. 2016;27(3):228–234.
   PubMed Web of Science ®Google Scholar
• Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222(2):148–156.
   PubMed Web of Science ®Google Scholar
• Calzavara-Pinton P, Rossi MT, Sala R, et al. The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two-compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g. G Ital Dermatol Venereol. 2011 Aug;146(4):295–299.
   PubMed Web of Science ®Google Scholar
• Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar-salicylic Acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol. 2014 Nov;59(6):579–583.
   PubMed Web of Science ®Google Scholar
• Saki N, Hosseinpoor S, Heiran A, et al. Comparing the efficacy of triamcinolone acetonide iontophoresis versus topical calcipotriol/betamethasone dipropionate in treating nail psoriasis: a bilateral controlled clinical trial. Dermatol Res Pract. 2018;2018:2637691.
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: a systematic review of direct and indirect evidence. Curr Med Res Opin. 2011 Jan;27(1):251–268.
   PubMed Web of Science ®Google Scholar
• van de Kerkhof P, de Peuter R, Ryttov J, et al. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin. 2011;27(1):225–238.
   PubMed Web of Science ®Google Scholar
• Menter A, Abramovits W, Colón LE, et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009 Jan;8(1):52–57.
   PubMed Web of Science ®Google Scholar
• Polańska A, Gaura T, Bowszyc-Dmochowska M, et al. Calcipotriol/betamethasone ointment compared to narrow-band UVB in plaque psoriasis: first clinical and ultrasonographic study. Int J Dermatol. 2019;58(1):108–113.
   PubMed Web of Science ®Google Scholar
• Anstey AV, Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol. 2006;45(8):970–975.
   PubMed Web of Science ®Google Scholar